Followers | 264 |
Posts | 36708 |
Boards Moderated | 1 |
Alias Born | 02/05/2003 |
Thursday, November 10, 2016 12:40:30 PM
$NMUS – at chart bottom – a serious, legitimate CBD research biotech company, in the right place, at the right time in American history. Fully SEC reporting and compliant, trading on the OTC, QB tier.
Nemus Bioscience, Inc. is a biopharmaceutical company that plans to develop and commercialize therapeutics from cannabinoids through an exclusive partnership with the University of Mississippi, the research hub of cannabinoid-based drugs, or CBDs, since 1965. The University of Mississippi ("UM") is federally permitted and licensed to cultivate cannabis for research and commercial purposes.
NOT a P&D – suitable for serious investors looking for 10x, 20x, 30x gains from current levels
From the 10-Q filed 11/10/16:
“As of November 8, 2016, there were 20,798,163 shares of the issuer's common stock, par value $0.001 per share, issued and outstanding.”
Small float, estimated 5 million shares. The share price moves easily and quickly, in both directions.
Top drugs in development:
NB1111 for the treatment of glaucoma.
NB1222 used for treating chemotherapy induced nausea and vomiting.
NB3111 for the treatment of methicillin-resistant Staphylococcus aureus.
NB2111 for use in treating chemotherapy induced peripheral neuropathy.
Nemus Bioscience, Inc. holds numerous patents relating to drug development and delivery systems that bypass the liver, which alters drug chemistry of medications taken orally.
Work on NB1111 has made Nemus Bioscience, Inc. a prime buyout candidate, as promising glaucoma drugs are highly sought in the $8 billion glaucoma industry worldwide, $2.3 billion in the U.S. alone.
Company website: www.nemusbioscience.com/home.html
Recent SKYE News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/13/2024 10:56:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 09/13/2024 09:18:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/04/2024 10:12:34 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 09/04/2024 09:25:07 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 08/09/2024 09:29:35 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2024 09:18:47 PM
- Beacon Biosignals Announces Strategic Collaboration with Skye Bioscience to Integrate Sleep Quality and Sleep Apnea Endpoints in CBEYOND™ Phase 2 Trial of Nimacimab for Obesity • GlobeNewswire Inc. • 07/24/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/10/2024 01:27:39 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/20/2024 04:15:09 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/17/2024 08:27:44 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 05/10/2024 08:19:14 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 05/10/2024 08:17:16 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 08:02:13 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM